150 related articles for article (PubMed ID: 24011332)
21. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
22. Long-term comparative effectiveness of Endeavor zotarolimus-eluting and everolimus-eluting stents in New York.
Qian F; Zhong Y; Hannan EL
Int J Cardiol; 2017 Aug; 241():437-443. PubMed ID: 28389121
[TBL] [Abstract][Full Text] [Related]
23. The role of everolimus-eluting and resolute zotarolimus-eluting stents in the treatment of coronary bifurcations.
Ferrarello S; Costopoulos C; Latib A; Naganuma T; Sticchi A; Figini F; Basavarajaiah S; Carlino M; Chieffo A; Montorfano M; Kawaguchi M; Naim C; Giannini F; Colombo A
J Invasive Cardiol; 2013 Sep; 25(9):436-40. PubMed ID: 23995715
[TBL] [Abstract][Full Text] [Related]
24. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
26. Comparison of twelve-month outcomes after percutanous coronary intervention with everolimus-eluting versus zotarolimus-eluting or sirolimus-eluting stents from the PROENCY (PROmus ENdeavor CYpher) registry.
Damman P; Abdel-Wahab M; Möllmann H; Richardt G; Chevalier B; Barragan P; Tijssen JG; Underwood P; Hamm CW
J Invasive Cardiol; 2012 Oct; 24(10):495-502. PubMed ID: 23043032
[TBL] [Abstract][Full Text] [Related]
27. Zotarolimus compared with everolimus eluting stents-angiographic and clinical results after recanalization of true coronary chronic total occlusions.
Markovic S; Lützner M; Rottbauer W; Wöhrle J
Catheter Cardiovasc Interv; 2016 Jul; 88(1):18-23. PubMed ID: 26945903
[TBL] [Abstract][Full Text] [Related]
28. Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR.
Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Heart Vessels; 2019 Feb; 34(2):237-250. PubMed ID: 30167772
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness of different contemporary drug-eluting stents in routine clinical practice: a multigroup propensity score analysis using data from the stent-specific, multicenter, prospective registries.
Kwon O; Kang SH; Lee JB; Ahn JM; Lee CH; Kang DY; Lee PH; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ;
Coron Artery Dis; 2019 Jun; 30(4):255-262. PubMed ID: 30883430
[TBL] [Abstract][Full Text] [Related]
30. Angiographic patterns of restenosis with 2nd generation drug-eluting stent: comparative analysis from a 10-year single-center experience .
Lee S; Yoon CH; Oh IY; Suh JW; Cho YS; Cho GY; Chae IH; Choi DJ; Youn TJ
Int Heart J; 2015; 56(1):6-12. PubMed ID: 25503656
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent - 3-Year Outcomes From the HOST-ASSURE Randomized Clinical Trial.
Kim CH; Park KW; Kang J; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Hur SH; Ryu JK; Lee BR; Park YW; Chae IH; Kim HS;
Circ J; 2019 Jun; 83(7):1489-1497. PubMed ID: 31155604
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis.
Piccolo R; Stefanini GG; Franzone A; Spitzer E; Blöchlinger S; Heg D; Jüni P; Windecker S
Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25858975
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.
Tandjung K; Sen H; Lam MK; Basalus MWZ; Louwerenburg JHW; Stoel MG; van Houwelingen KG; de Man FHAF; Linssen GCM; Saïd SAM; Nienhuis MB; Löwik MM; Verhorst PMJ; van der Palen J; von Birgelen C
J Am Coll Cardiol; 2013 Jun; 61(24):2406-2416. PubMed ID: 23602769
[TBL] [Abstract][Full Text] [Related]
34. Comparison of zotarolimus- and everolimus-eluting stents in patients with ST-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention.
Ahmed K; Jeong MH; Chakraborty R; Ahmed S; Hong YJ; Sim DS; Park KH; Kim JH; Ahn Y; Kang JC; Cho MC; Kim CJ; Kim YJ;
J Cardiol; 2014 Oct; 64(4):273-8. PubMed ID: 24631465
[TBL] [Abstract][Full Text] [Related]
35. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
36. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
[TBL] [Abstract][Full Text] [Related]
37. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcomes after Resolute zotarolimus-eluting stent implantation in patients with ST-segment elevation acute myocardial infarction: insights from the RESOLUTE All Comers Trial and the RESOLUTE Global Clinical Trial Program.
Di Mario C; Serruys PW; Silber S; Lu S; Wang W; Widimský P; Xu B; Windecker S
EuroIntervention; 2016 Nov; 12(10):1207-1214. PubMed ID: 27866129
[TBL] [Abstract][Full Text] [Related]
39. Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State.
Hannan EL; Zhong Y; Wu C; Walford G; Holmes DR; Jacobs AK; Stamato NJ; Venditti FJ; Sharma S; Fergus I; King SB
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1097-105. PubMed ID: 22707353
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes of contemporary drug-eluting stents in patients with and without diabetes mellitus: Multigroup propensity-score analysis using data from stent-specific, multicenter, prospective registries.
Kwon O; Lee JB; Ahn JM; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ;
Catheter Cardiovasc Interv; 2020 Aug; 96(2):243-252. PubMed ID: 31478593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
